Paul A. Friedman
Principal executive officer pay for Paul A. Friedman, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) FY2021–FY2023
Beat peersTSR 174% vs peer group -7% over FY2021–FY2023
Turnaround$100 invested moved from behind the peer group ($76.00 vs $99.00) to ahead ($208.00 vs $92.00) over FY2021–FY2023
Pay cut while stock roseCAP $1,210,321→-$29,110,282 while $100 invested went $76.00→$208.00 (FY2021–FY2023)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $5.3M | $1.2M |
| FY2022 | $5.4M | $38.4M |
| FY2023 | $9.6M | -$29.1M |
The company's "$100 invested" index ran $76.00 at FY2021 → $208.00 by FY2023 — an annualized return of 65.4%.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) FY2020–FY2023
Beat peersTSR 70% vs peer group -27% over FY2020–FY2023
Turnaround$100 invested moved from behind the peer group ($122.00 vs $126.00) to ahead ($208.00 vs $92.00) over FY2020–FY2023
Pay cut while stock roseCAP $6,480,322→$2,371,068 while $100 invested went $122.00→$208.00 (FY2020–FY2023)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2020 | $4.5M | $6.5M |
| FY2021 | $5.3M | $1.2M |
| FY2022 | $5.4M | $38.4M |
| FY2023 | $9.6M | $2.4M |
The company's "$100 invested" index ran $122.00 at FY2020 → $208.00 by FY2023 — an annualized return of 19.5%.
Track record
2 measurable tenures in the pay-versus-performance disclosure window. Best annualized TSR: 65.4%/yr at MDGL ( FY2021–FY2023). See the CEO track-record ranking for context.
All disclosed tenures: 5 years across 1 companies. Shown per company only: the disclosed windows overlap, so chaining them would count the same years twice.